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Redesigning the substrate specificity of the hepatitis C virus 
NS3 protease
Cristina Maria Failla, Elisabetta Pizzi, Raffaele De Francesco 
and Anna Tramontano
Background: Hepatitis C Virus (HCV) non-structural protein 3 (NS3) encodes a
trypsin-like serine protease that catalyzes the cleavages at the NS3/NS4A,
NS4A/NS4B, NS4B/NS5A and NS5A/NS5B junctions in the viral polyprotein
and that shows a preference for a cysteine as the P1 residue. 
Results: We describe here a partial model of the HCV NS3 protease which
allowed us to predict the position of the secondary structure elements of the
enzyme and of the residues involved in its specificity. By replacing these with the
corresponding residues of Streptomyces griseus protease B, we obtained a
protease that, similar to the bacterial protein and unlike the wild-type enzyme, is
able to cleave a substrate containing a phenylalanine in the P1 position.
Conclusions: These results confirm the reliability of our model and represent
one of the few examples of redesign of a serine protease substrate specificity
directed by molecular modelling.
Introduction
Many human and animal viruses encode proteases that
play important roles at different stages in the infection
cycle and are essential for virus infectivity [1]. These pro-
teases have, therefore, been considered attractive targets
for chemotherapeutic intervention, particularly because
they have unusual cleavage specificities that differ from
those of host proteases. 
Hepatitis C virus (HCV) is the major etiologic agent of
both parenterally transmitted and sporadic non-A, non-B
hepatitis (NANB-H) [2,3]. The development of cirrhosis
and hepatocellular carcinoma in individuals with NANB-
H suggests a causative linkage between HCV infection
and hepatocarcinogenesis [4]. Neither effective therapy
for HCV-associated chronic hepatitis nor a vaccine against
the virus has been developed to date.
The HCV virion has a positive-strand RNA genome of
about 9.5 kb [5–7]. The genomic RNA contains a single
open reading frame encoding a polyprotein of about 3000
amino acids. The putative structural proteins ‘core’ and
the envelope glycoproteins E1 and E2 are released from
the N-terminal part of the HCV polyprotein by cellular
peptidases [8], whereas a virus-encoded metalloprotease
is responsible for the cleavage between NS2 and NS3
[8,9]. It has been demonstrated that the proteolytic
cleavage at the NS3/NS4A, NS4A/NS4B, NS4B/NS5A,
and NS5A/NS5B junctions is mediated by a virus-
encoded serine protease, contained within NS3, that
bears homology to the small cellular proteases of the
trypsin superfamily [8,10–14]. In addition to the NS3
serine protease, the NS4A protein is required for cleav-
age at the NS3/NS4A and NS4B/NS5A sites and it
increases the efficiency of cleavage at the NS5A/NS5B
and NS4A/NS4B junctions [15–18]. Processing at the
NS3/NS4A site is unique, inasmuch as it occurs in cis
[13]. This finding indicated that the cleavage of the
latter site is an intramolecular event. Interestingly, the
NS3/NS4A cleavage site differs from the others in that
the processing takes place between a threonine and a
serine (or in one case an alanine) residue, whereas the
remainder are cleaved between a cysteine and a serine
[13,19,20].
The structure of the HCV NS3 protease is unknown. To
overcome this lack of structural information, we built a
model of the specificity pocket of NS3 based on the
known structures of trypsin-like serine proteases and on
the conserved pattern of the protease sequences among
different HCV strains [20]. In our model, the physico-
chemical environment and the shape of the pocket are
determined primarily by phenylalanine 213 (according to
the chymotrypsin numbering scheme). Visual inspection
of the modelled pocket suggested that the P1 residue of
the substrate could be a cysteine or a serine. In addition,
the pocket appeared to be very hydrophobic and closed
by the aromatic ring of the phenylalanine. As the sul-
phydryl group of cysteine has been shown to interact
favourably with the aromatic ring of phenylalanine, cys-
teine was considered the most reasonable P1 residue.
This prediction was subsequently confirmed by N-termi-
nal sequencing of the processed NS4B, NS5A and NS5B
proteins [19,20].
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We extended our model to a larger part of the enzyme
sequence that includes all the secondary structure ele-
ments known to be present in the trypsin-like protease
fold. To test the validity of the model, we used it as a
guide for site-specific mutagenesis aimed at modifying the
specificity of the protease. Our rationale was to replace the
residues predicted to form the specificity pocket of NS3
with the corresponding ones of Streptomyces griseus protease
B (SGPB) [21], a protease of known structure able to rec-
ognize a phenylalanine residue in the P1 position of the
substrate.
The substrate specificities of the serine proteases trypsin
[22], -lytic protease [23], subtilisin [24] and granzyme B
[25] have already been successfully altered without
destroying the catalytic activity of the enzyme. These
mutagenesis experiments were based on the crystal struc-
tures of the enzymes, with the exception of the granzyme
B protease, for which the authors used a homology model
built using rat mast cell protease 2 as a template and based
on about 50% sequence identity between the target and
the template enzyme. 
No protease of known structure shares more than 13%
sequence identity with the HCV NS3 protease, so our
model had to be confined to the most structurally con-
served regions of the protease structures. Even in these
regions, its reliability is limited, especially as far as atomic
details are concerned.
Nevertheless, we were able to design a mutant of the
specificity pocket of the enzyme and show here that the
resulting NS3 mutant acquires the ability to cleave a sub-
strate where the P1 residue is a phenylalanine, thus sup-
porting the correctness of our alignment of the NS3
protease sequence with the sequences of known proteases
and of the resulting partial structural model. 
Results
Substrate requirements for the NS3-dependent cleavage
To test the substrate specificity of the NS3 protease, we
made three different substitutions in the P1 residue of the
NS5A/B cleavage site and studied the activity of the NS3
protease on the mutagenized substrates using transient
expression in eukaryotic cells. Plasmids encoding either the
wild-type or the mutated substrates were transiently
expressed in HeLa cells together with pCite(NS3–4A)
(Fig. 1). The latter plasmid encodes a protein precursor
containing both the NS3 serine protease and the NS4A
cofactor. Cotransfection of pCite(NS3–4A) with the
plasmid encoding the wild-type NS5A–5B precursor,
pCite(NS5A–B), resulted in the total proteolytic cleavage
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Figure 1
Processing of wild-type and mutated HCV
NS5A–NS5B substrate. Plasmid
pCite(NS3–4A) was transfected with
pCite(NS5A–B) (lanes 1–3), with
pCite(NS5A–B: Cys2419→Thr) (lanes 4–6);
pCite(NS5A–B: Cys2419→Phe) (lanes 7–9)
and pCite(NS5A–B: Cys2419→Arg) (lanes
10–12). Cell lysates were immunoprecipitated
with anti-NS3 (3, lanes 1,4,7,10), anti-NS5A
(5A, lanes 2,5,8,11) and anti-NS5B (5B,
lanes 3,6,9,12). The positions of the relevant
HCV proteins immunoprecipitated with anti-
HCV antibodies are indicated. Sizes of the
molecular weight standards are indicated in
kDa.
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of the protein substrate: two fragments of 56 kDa and
65 kDa were recognized by the anti-NS5A and NS5B antis-
era, respectively (Fig. 1, lanes 2,3). The NS3–4A precursor
was also completely processed, releasing a protein of
70 kDa that could be immunoprecipitated with anti-NS3
antiserum (Fig. 1, lanes 1,4,7,10). Cotransfection of
pCite(NS3–4A) with pCite(NS5A–5B: Cys2419→Thr),
which encodes a substrate with a threonine residue in the
P1 position, resulted in a partial proteolytic conversion of
the 115 kDa precursor into the two product proteins (Fig. 1,
lanes 5,6). This result is in agreement with the model of
the specificity pocket of the enzyme that considered a P1
threonine a poorer substrate for the protease. Cotransfec-
tion of pCite(NS3–4A) with pCite(NS5A–5B:
Cys2419→Phe) or pCite(NS5A–B: Cys2419→Arg), which
encode substrates with phenylalanine or arginine in the P1
position, respectively, did not lead to any proteolytic cleav-
age: anti-NS5A and anti-NS5B antisera recognized only the
precursor 115 kDa protein (Fig. 1, lanes 8,9,11–12). These
results are in agreement with the model proposed and with
the recent analysis of the NS3 protease cleavage specificity
carried out by other groups in vitro and in vivo [26,27].
Structural analysis of HCV protease
The great wealth of structural information on serine pro-
teases can be exploited to try to derive structural informa-
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Figure 2
4ptp     IVGGYTCGANTVPYQVSLNSGYHFCGGSLINSQWVVSAAHCYKSGIQVRLGEDNINVVEGNEQFISASKSIVHPSYNSNTLNNDIMLIKLKSAASLNSRVASI
1brb     IVGGYTCQENSVPYQVSLNSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLEGNEQFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNARVATV
1trn     IVGGYNCEENSVPYQVSLNSGYHFCGGSLINEQWVVSAGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPQYDRKTLNNDIMLIKLSSRAVINARVSTI
3est     VVGGTEAQRNSWPSQISLQywAHTCGGTLIRQNWVMTAAHCVdltFRVVVGEHNLNQNNGTEQYVGVQKIVVHPYWNTDDvgYDIALLRLAQSVTLNSYVQLG
5chA     IVNGEEAVPGSWPWQVSLQdgFHFCGGSLINENWVVTAAHCGVtsDVVVAGEFDQGSSSEKIQKLKIAKVFKNSKYNSLTINNDITLLKLSTAASFSQTVSAV
3rp2     IIGGVESIPHSRPYMAHLDIvrVICGGFLISRQFVLTAAHCKGREITVILGAHDVRKRESTQQKIKVEKQIIHESYNSVPNLHDIMLLKLEKKVELTPAVNVV
1hcg     IVGGQECKDGECPWQALLInnEGFCGGTILSEFYILTAAHClaKRFKVRVGDRNTEQEEGGEAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPA
1etr     IVEGQDAEVGLSPWQVMLFrqELLCGASLISDRWVLTAAHCLldDLLVRIGKHSRTRYERVEKISMLDKIYIHPRYNweNLDRDIALLKLKRPIELSDYIHPV
1hne     IVGGRRARPHAWPFMVSLQLRghFCGATLIAPNFVMSAAHCvvRAVRVVLGAHNLSRREPTRQVFAVQRIFED.GYDPVNLLNDIVILQLNGSATINANVQVA
1sgt     VVGGTRAAQGEFPFMVRLS...MGCGGALYAQDIVLTAAHCVstSITATGGVVDLQSG..AAVKVRSTKVLQAPGYNG..TGKDWALIKLAQPIN....QPTL
1mct     ............................................................................NGNTLDNDIMLIKLSSPATLNSRVATV
2pka     IIGGRECEKNSHPWQVAIYhsSFQCGGVLVNPKWVLTAAHCKNDNYEVWLGRHNLFENENTAQFFGVTADFPHPGFNLSdySHDLMLLRLQSPAKITDAVKVL
2sga     ............IAGgaITTGGSRCSlfNVsvAHALTAGHCtsASWSI..................GTRTGTs.......pNNDYGIIRHSNPa.....aDGr
1ton     ............................................................................PVHDHSNDLMLLHLSEPADITGGVKVI
1arb     .................................................................................TSDFTLLELNNAANPAFNLFWA
NS3p     ............NQVeeVQVVSTATQslATcnGVCWTVYHGasATLAa..................pITQMYt.......vDQDLVGWPKPPGa.....sLt.
4ptp     SLPTSCASAGTQCLISGWGNTKSSGTSYPDVLKCLKAPILSDSSCKSAYPGQITSNMFCAGYLEGGKDSCQGDSGGPVVCSGKLQGIVSWGSGCAQKNKPGVY
1brb     ALPSSCAPAGTQCLISGWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKGSCQGDSGGPVVCNGELQGIVSWGYGCALPDNPDVY
1trn     SLPTAPPATGTKCLISGWGNTASSGADYPDELQCLDAPVLSQAKCEASYPGKITSNMFCVGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWGDGCAQKNKPGVY
3est     VLPrtILANNSPCYITGWGLTRT.NGQLAQTLQQAYLPTVDYAICssYWGSTVKNSMVCAGGD.GVRSGCQGDSGGPLHClyAVHGVTSFVsgCNVTRKPTVF
5cha     CLPsdDFAAGTTCVTTGWGLTRY..ANTPDRLQQASLPLLSNTNCKKYWGTKIKDAMICAGA..SGVSSCMGDSGGPLVCkwTLVGIVSWGSscSTS.TPGVY
3rp2     PLPsdFIHPGAMCWAAGWGKTGV.RDPTSYTLREVELRIMDEKACVDYR..YYEyfQVCVGSPTTLRAAFMGDSGGPLLCAGVAHGIVSYGHPDAK..PPAIF
1hcg     CLPErlMTQ.KTGIVSGFGRTh......sTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSGGPHVTryFVTGIVSWGEGCARKGKYGIY
1etr     CLPDklLHAGFKGRVTGWGNRRETweVQPSVLQVVNLPLVERPVCKASTRIRITDNMFCAGYKp.rGDACEGDSGGPFVMkwYQMGIVSWGEGCDRDGKYGFY
1hne     QLParRLGNGVQCLAMGWGLLG.RNRGIASVLQELNVTVV.TSLC........RRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRgcASGLYPDAF
1sgt     KIATTtyNQG.TFTVAGWGANRE.GGSQQRYLLKANVPFVSDAACRSAYGNELvnEEICAGYptGGVDTCQGDSGGPMFRkwIQVGIVSWGYGCARPGYPGVY
1mct     SLPRSCAAAGTECLISGWGNTKSSGSSYPSLLQCLKAPVLSNSSCKSSYPGQITGNMICVGFLQGGKDSCQGDSGGPVVCNGQLQGIVSWGYGCAQKNKPGVY
2pka     ELPTQEPELGSTCEASGWGSIEPgdFEFPDEIQCVQLTLLQNTFCADAHPDKVTESMLCAGYLPGGKDTCMGDSGGPLICNGMWQGITSWGHtcGSANKPSIY
2sga     tTAG.NAFVGQAVQRSGSTT............GLRSGSVTGl.........iVYG.MIQTn......cAQPGDSGGSLFAGSTALGLTSGGSGNCRTGGTTFY
1ton     DLPTKEPKVGSTCLASGWGSTNPs.mVVSHDLQCVNIHLLSNEKCI..ETYkvTDVMLCAGEMEGGKDTCAGDSGGPLICDGVLQGITSGGAtcAKPKTPAIY
1arb     GWDRRDQNYP.GAIAIHHPN........VAEKRISNssPTSf........gGAGTTHLNVQWQPSGGVTEPGSSGSPIYSPerVLGQLHGGPsc.aTGtsDQY
NS3p     tCGS.SDLYLVTRHA.................DVIPVRRGDS...........RGSLLSPRp.....sYLKGSSGGPLLCpgHAVGIFRAAVCT..RG.VAKA
4ptp   TKVCNYVSWIKQTIASN
1brb   TKVCNYVDWIQDTIAAN
1trn   TKVYNYVKWIKNTIAAN
3est   TRVSAYISWINNVIASN
5cha   ARVTALVNWVQQTLAAN
3rp2   TRVSTYVPWINAVIN..
1hcg   TKVTAFLKWIDRSMKTR
1etr   THVFRLKKWIQKVIDR.
1hne   APVAQFVNWIDSIIQ..
1sgt   TEVSTFASAIASAARTL
1mct   TKVCNYVNWIQQTIAAN
2pka   TKLIFYLDWIDDTITEN
2sga   QPVTEALSAYG......
1ton   AKLIKFTSWIKKVMKEN
1arb   GRVFTSWtrLSDWDPAS
NS3p   VDFV.............
Alignment of part of the HCV NS3 protease sequence with the
structural alignment of selected proteases of known structure. The
complete sequence of bovine -trypsin is shown in the first line.
Residues before and after a deletion in the other sequences are in
lowercase. Regions in red and green are -strand and -helices,
respectively. See Materials and methods for the databank codes.
tion on the HCV NS3 protease, even though the level of
sequence identity between this enzyme and any other
protease of known structure is very low. We selected a set
of representative proteases belonging to different classes
as defined by scop [28]. Their structural alignment was
extracted from the FSSP database (entry 4ptp.fssp) [29]
and is shown in Figure 2. This structural alignment was
used to obtain a sequence profile to which we could man-
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Figure 3
HCV  NS3p  KNQVEGEVQVVSTATQSFLATCVNGVCWTVYHGAGSKTLAAPKGPITQMYTNVDQDLVGWPKPPGARSLTPCTCG
GB-A NS3p  PSEHHGNVVVLGTSTTRSMGCCVNGVVYTTYHGTNARPMAGPFGPVNARWWSASDDVTVYPLPNGASCLQACKCQ
GB-B NS3p  PRTWTGTIFRLGSLATSYMGFVCDNVLYTAHHGSKGRRLAHPTGSIHPITVDAANDQDIYQPPCGAGSLTRCSCG
             ***********    ******* *******            ******
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HCV  NS3p  SSDLYLVTRHADVIPVRRRGDSRGSLLSPRPVSYLKGSSGGPLLCPFGHAVGIFRAAVCTRGVAKAVDFV.PVES...
GB-A NS3p  PTGVWVIRNDGALCHGTL..GKVVDLDMPAELSDFRGSSGSPILCDEGHAVGMLISVLHRGSRVSSVRYTKPWET...
GB-B NS3p  ETKGYLVTRLGSLVEVNKSDDPYWCVCGALPMAVAKGSSGAPILCSSGHVIGMFTAARNSGGSVSQIR.VRPLVC...
             *******   ****               *****      **     **********    * *
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Alignment of HCV NS3 sequence with the corresponding region of
hepatitis GB-A and GB-B viruses. We compare here the position of 
-strands predicted by the PHD method (*) with the regions
corresponding to -strands in the alignment shown in Fig. 2 (). The
catalytic serine is boxed.
Figure 4
Molscript [40] representation of the structure
of bovine -trypsin (databank code 4ptp) [41].
The regions in red are those for which we
could obtain an alignment with the HCV NS3
sequence.
ually align a substantial part of the HCV NS3 sequence as
shown in Figure 2. The aligned region is predicted to
contain all the 12 -strands that form the core structure of
the conserved trypsin-like serine protease fold.
Using a completely independent approach, we aligned a
set of HCV-related sequences (Fig. 3), including a
number of different serotypic sequences not shown in the
figure and the sequences of NS3 of hepatitis GB-A and
GB-B viruses [30]. This alignment was used as input for
the PHD secondary structure prediction server [31], the
reliability of which is evaluated to be above 70%. The
resulting prediction is shown in Figure 3, where we also
compare the PHD secondary structure prediction with
that deriving from the multiple alignment. The agreement
between the two predictions is reasonably good, especially
in light of the fact that the two procedures are based on
completely different data and assumptions and are there-
fore totally independent from each other. It is worth
noting, however, that the region in which there is more
disagreement between the two assignments is that sur-
rounding the catalytic serine. The region immediately
preceding the serine is quite variable among the various
proteases, but always includes a -strand and a loop. The
PHD prediction positions a -strand immediately before
the serine, which would make it topologically impossible
to maintain the relative position of the catalytic triad,
whereas the prediction deriving from our alignment is
more consistent with the protease functional require-
ments. We could not, however, exclude the possibility
that this region undergoes some substantial rearrangement
compared to other proteases. Only a detailed structural
characterization of the protein can clarify this point and, as
can be seen from Figure 4, our structural alignment
includes only about 70% of the HCV NS3 sequence,
which precludes the possibility of building a more
detailed model with reasonable accuracy. Our results can
be tested experimentally, though, using the structural
alignment to attempt the modification of some of the
enzyme properties in a predictable way. Consequently, we
mutated the predicted specificity pocket of the enzyme in
order to modify its substrate specificity.
Mutagenesis of the protease specificity pocket
The optimal P1 residues for substrate of SGPB are
phenylalanine, tyrosine and, to a lesser extent, leucine
[32]. The specificity pocket of this protease is formed by
the side-chains of alanine 190, threonine 213, glycine 216
and threonine 226. Figure 5 shows a schematic drawing of
the specificity pockets of the NS3 model and of the bacte-
rial protease. Both proteins have a threonine in position
226, which was consequently left unchanged. In positions
213, 216 and 190, the NS3 protease has a phenylalanine,
an alanine and a tyrosine. In our model, the latter does not
contribute to the specificity of the enzyme [20]. Conse-
quently, we mutated only the phenylalanine and the
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Figure 5
Schematic representation of the modelled specificity pocket of (a)
NS3, (b) Streptomyces griseus protease B and (c) the mutant. The
position of the amino acid label (inside or outside the pocket) indicates
the observed (in [b]) or predicted (in [a] and [c]) orientation of its side-
chain. The mutant bears two substitutions: Phe213→Thr and
Ala216→Gly.
211G
I
 F
R
A
216A
226T
189S
Y
L
K
G S
195S
(a)
211G
L
 T
S
G
216G
226T
189C
A
E
P
G D
195S
(b)
211G
I
 T
R
A
216G
226T
189S
Y
L
K
G S
195S
(c)
alanine to the corresponding residues of the SGPB
sequence (threonine and glycine, respectively). 
To determine the activity of the mutant protease encoded
by pCite(NS3–4A: Phe1180→Thr; Ala1183→Gly) protease,
we cotransfected this plasmid with substrates bearing dif-
ferent residues in P1, namely cysteine, threonine, pheny-
lalanine and, as a control, arginine. As shown in Figure 6
(lanes 1,4,7,10), the intramolecular cleavage between NS3
and NS4A is impaired within the mutated NS3–4A precur-
sor. This does not affect the trans-cleavage activity of the
NS3 protease, as we have previously demonstrated that
maturation of the NS3–4A precursor is not necessary for
protease activity [33]. Thus, the expected cleavage products
of 56 kDa and 65 kDa were identified by immunoprecipita-
tions with the appropriate antisera of the extracts obtained
from cells expressing the protease and the substrate with
cysteine (Fig. 6, lanes 2–3) or threonine (Fig. 6, lanes 5–6)
as P1 residues. The catalytic efficiency of this mutated
protein on the substrate containing a cysteine as the P1
residue was partially reduced with respect to the wild-type
protease. Unlike the wild-type protease, however, the
mutated enzyme was also able to cleave the substrate with a
phenylalanine residue in the P1 position (Fig. 6, lanes 8–9).
In addition, the control substrate with an arginine residue in
P1 was still not cleaved by the mutant protease (Fig. 6,
lanes 11–12) suggesting that this newly engineered enzyme
maintains a high degree of substrate specificity.
Discussion
The specificity of serine proteases is determined mainly
by their specificity pocket. Different residues in this
region give rise to the great variety of substrate specifici-
ties of this class of enzymes. 
Given the pharmacological relevance of HCV, it is very
important to gain some insights into the structural basis of
the specificity of its NS3 serine protease. So far, however,
no crystallization data have been reported on this enzyme.
Reliable detailed models of proteins can be obtained only
when the sequence identity between the target and tem-
plate proteins is significant and, more importantly, the reli-
ability of the final model and its accuracy are directly
related to the sequence similarity. When the sequence
identity between the target protein and a protein of known
structure drops below 20%, as in the case of the NS3 pro-
tease, even the detection of the similarity becomes very
problematic. In some cases, including those of serine pro-
teases, it is possible to take advantage of the presence of
conserved ‘diagnostic’ sequence patterns, but then the
major obstacle toward the construction of a model
becomes the quality of the sequence alignment. We were
able to obtain a partial sequence alignment of the NS3
protease with other known serine proteases by developing
a sequence profile obtained via the structural superposi-
tion of a selected set of serine proteases of known struc-
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Figure 6
Specificity of the mutant protease. Plasmid
pCite(NS3–4A: Phe1180→Thr;
Ala1183→Gly; Thr1657→Phe) was
transfected either with pCite(NS5A–B) (lanes
1–3), or with one of the substrate-encoding
plasmids pCite(NS5A–B: Cys2419→Thr)
(lanes 4–6); pCite(NS5A–B: Cys2419→Phe)
(lanes 7–9); pCite(NS5A–B: Cys2419→Arg)
(lanes 10–12). Cell lysates were
immunoprecipitated with anti-NS3 (3, lanes
1,4,7,10), anti-NS5A (5A, lanes 2,5,8,11)
and anti-NS5B (5B, lanes 3,6,9,12)
antibodies. The positions of the relevant HCV
proteins are indicated. Sizes of the molecular
weight standards are indicated in kDa.
90-
69-
45-
30-
(kDa)
MW
-NS5AB
-NS5B
-NS5A
α3α5A α5B α3α5A α5Bα3α5A α5Bα3α5A α5B
 1    2    3             4    5   6                7    8    9             10  11  12
NS3-4A(Phe1180    Thr; Ala1183    Gly)
NS5A-5B
P1 :Cys P1 :ArgP1 :PheP1 :Thr
NS3-4A
NS3
tures. We obtained a model that, although incomplete,
comprises the region of the specificity pocket and all the
β-strands conserved in the trypsin-like serine protease
fold. The first test of the model was its ability to predict, in
a blind test, the specificity of the protease [20]. The
success of this test is certainly encouraging, but it is not yet
sufficient to guarantee the correctness of the alignment of
the residues forming the specificity pocket of the enzyme.
The best test for a model such as ours is to use it to modify
the enzyme’s properties in a predictable way. Such experi-
ments, although difficult given our very poor understand-
ing of the rules relating to sequence and structure in
proteins, represent the only way to gain confidence in a
proposed model.
Our experiment was successful. The redesigned enzyme
acquired, through only two mutations, the ability to cleave
the substrate recognized by SGPB, an enzyme of known
structure used as template, and this strongly supports the
reliability of our model.
The mutant enzyme is not as active as its wild-type coun-
terpart and this is not at all surprising considering the
strong requirements imposed by the catalytic mechanism
on the structure of the enzyme. The mutant still recog-
nizes the original NS3 substrates, so one could describe
the result more as a broadening of the specificity in the
desired direction (the mutant enzyme does not recognize
the control arginine substrate) rather than a switch in
specificity. It is worth noting, however, that to the best of
our knowledge there is no report in the literature of
kinetic data for SGPB with a cysteine substrate, so we
cannot exclude the possibility that the template protease
is also able to recognize this amino acid in the P1 position.
We believe that the success of our redesign, which pre-
sented a priori a number of pitfalls, is highly supportive of
our partial model. 
Materials and methods
Cells and virus
HeLa cells, obtained originally from the American Type Culture Collec-
tion, were grown in Dulbecco’s modified Eagle’s medium (DMEM) con-
taining 10% fetal calf serum (FCS). Vaccinia virus VTF7-3 [34] was
grown in RK13 cells cultured in minimum essential medium (MEM)
containing 10% FCS.
Construction of recombinant plasmids
HCV cDNA clones of the HCV-BK isolate were used for all plasmid
constructions [7]. DNA fragments deriving from HCV cDNA were
inserted downstream of the 5′ untranslated region of encephalomy-
ocarditis virus and under the control of a T7 promoter in the pCite-1
vector (Novagen) [35,36] in the appropriate translational reading frame
and followed by a termination codon. All the plasmids described below
were obtained using standard recombinant DNA technology [37].
Plasmids pCite(NS3–4A) and pCite(NS5A–B) have been described
previously [16].
Site-directed mutants in the NS3 substrate-binding pocket
pCite(NS3–4A: Phe1180→Thr; Ala1183→Gly) were generated step-
wise by PCR-mediated site-directed mutagenesis [38]. The mutant
DNA fragments thus generated were recloned into the parental
plasmid using restriction sites flanking the mutations and were subse-
quently sequenced. The triplet coding for phenylalanine 1180, TTC,
was replaced by ACC, coding for threonine; the GCC triplet coding
for alanine was replaced by a GGC triplet coding for glycine.
pCite(NS5A–B: Cys2419→Thr), pCite(NS5A–B: Cys2419→Phe)
and pCite(NS5A–B: Cys2419→Arg) were obtained by PCR-medi-
ated mutagenesis as described above for the NS3 mutants. The
triplet TGC encoding cysteine 2419 was substituted with the triplets
ACC, TTC or CGC, coding for threonine, phenylalanine and arginine
respectively.
Preparation of labelled extracts
HeLa cells seeded at a density of 4 × 105 cells per 6 cm plate were
infected with vaccinia virus vTF7-3 at a multiplicity of 5 PFU per cell,
as previously described [13]. After adsorption for 30 min at 37°C,
3 ml of DMEM supplemented with 10% FCS were added. Cells were
incubated for an additional 30 min at 37°C. Recombinant plasmid
DNA was precipitated by the calcium phosphate method [37] and
added directly to each plate. At 3 h post-transfection, the medium
was replaced with MEM lacking methionine (GIBCO) and the cells
were starved for 1 h at 37°C. Cells were then radiolabelled for 3 h
with 300 Ci of Tran35S-label (ICN) in 2 ml of MEM lacking methion-
ine supplemented with 2% dialyzed FCS. Cells were harvested and
resuspended in IPB150 (20 mM Tris/HCl pH 8, 150 mM NaCl, 1%
Triton) supplemented with 1 mM phenylmethylsulfonyl fluoride, 1 mM
EDTA, and 1 mM dithiothreitol. Immunoprecipitations were con-
ducted on denatured extracts with HCV region-specific rabbit poly-
clonal antisera, as described previously [13,20]. Analytical gel
electrophoresis of the immunoprecipitated products were performed
as described previously [20].
Molecular modelling
The FSSP database [29] was used to obtain the structural alignment of
known proteases. PHD [31] was used for the secondary structure pre-
diction and all other analyses were performed using the program
Insight [39].
Databank codes of proteases of known structure used in this work:
4ptp, bovine -trypsin; 1brb, rat anionic trypsin; 1trn, human trypsin 1;
3est, porcine pancreatic elastase; 5cha, -chymotrypsin; 3rp2, rat
mast cell protease; 1hcg, human factor Xa; 1etr, bovine thrombin;
1hne, human neutrophil elastase; 1sgt, Streptomyces griseus trypsin;
1mct, porcine -trypsin; 2pka, porcine pancreatic kallikrein; 2sga,
Streptomyces griseus protease A; 1ton, rat submaxillary gland serine
protease; 1arb, achromobacter lyticus protease.
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